Search Results

Business

HuidaGene and Synthego Announce Licensing Agreement on Next-Generation Gene Editing Enzyme, hfCas12Max

HuidaGene Therapeutics and Synthego Corporation (“Synthego”), a leading provider of innovative CRISPR solutions for developing cell and gene therapies, proudly announce a partnered licensing agreement for the high-fidelity Cas12 CRISPR nuclease (hfCas12Max).

May 29, 2024

·

3 min read

Biotech Bay

Synthego Announces CEO Transition to Focus on Enabling CRISPR Therapeutics

Synthego Corporation, a leading provider of genome engineering solutions, announced that Paul Dabrowski will step down as Chief Executive Officer, effective immediately.

March 27, 2024

·

3 min read

Business

Synthego and SeQure Dx Partner to Provide Comprehensive Off-Target Analysis Services for CRISPR-Based Therapeutics Developers

Synthego and SeQure Dx have announced a strategic partnership to provide CRISPR-based therapeutics developers with comprehensive off-target editing analytical services that include best-in-class technology and turn-key end-to-end development solutions.

January 23, 2024

·

4 min read

Drug Development

Synthego Bridges Critical Preclinical Gap to Accelerate CRISPR-based Cell and Gene Therapies

Synthego, a leading provider of genome engineering solutions, announced the launch of its IND-enabling gRNAs, a transformative product offering that revolutionizes the CRISPR-based cell and gene therapy preclinical pipeline.

October 4, 2023

·

2 min read

Business

Synthego and ATCC Enter Alliance for Cutting-Edge Gene Editing of Mammalian and Mouse Cell Lines

Synthego, a leading genome engineering company, is pleased to announce a groundbreaking partnership with ATCC.

June 28, 2023

·

4 min read

Business

Synthego and bit.bio Expand Strategic Partnership to Build a Platform for the Development of Safer and More Efficient Genetic Engineering of Human Cells for Cell Therapies

Synthego and bit.bio announced a strategic partnership to build a platform centered on the implementation of synthetic circuitry in cells for therapeutic application.

August 24, 2023

·

4 min read

Biotech Bay

Synthego Announces Invalidation of Agilent Patents in CRISPR Dispute

Synthego Corp. has announced a victory in its dispute with Agilent Technologies, Inc., regarding two of Agilent’s patents which have been invalidated by a ruling of the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office.

May 17, 2023

·

2 min read

Biotech Bay

Synthego Opens State-of-the-Art GMP Guide RNA Manufacturing Facility to Enable CRISPR Genomic Medicines

Synthego Corp., a leading provider of genome engineering solutions, announced the opening of its state-of-the-art GMP synthesis facility.

May 11, 2023

·

4 min read

Biotech Bay

Synthego Introduces CRISPR Discovery Partners to Streamline CRISPR-Driven Drug Discovery Research

Synthego Corp. announced the launch of its service partner ecosystem, CRISPR Discovery Partners, designed to accelerate drug discovery by providing a seamless research workflow from CRISPR editing to phenotypic data and downstream services.

March 16, 2023

·

3 min read

Business

Synthego Expands Capabilities of Halo Platform with Next-Generation Manufacturing Facility

Synthego, the genome engineering company, announced that the company has broken ground on a 20,000-square-foot manufacturing facility designed to accelerate translational and clinical research development timelines for cell and gene therapies to as little as a year.

July 26, 2022

·

2 min read